Population pharmacokinetics and pharmacodynamics of cysteamine in nephropathic cystinosis patients
Open Access
- 1 January 2011
- journal article
- clinical trial
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 6 (1) , 86
Abstract
Nephropathic cystinosis is an autosomal recessive disorder resulting in an impaired transport of cystine trough the lysosomal membrane causing an accumulation of free cystine in lysosomes. The only specific treatment for nephropathic cystinosis is cysteamine bitartrate. This study was aimed to describe the relationship between cysteamine plasma concentrations and white blood cell cystine levels, and to simulate an optimized administration scheme to improve the management of patients with cystinosis.Keywords
This publication has 12 references indexed in Scilit:
- The mechanisms of microtubule catastrophe and rescue: implications from analysis of a dimer-scale computational modelMolecular Biology of the Cell, 2012
- Importance of Shrinkage in Empirical Bayes Estimates for Diagnostics: Problems and SolutionsThe AAPS Journal, 2009
- Mechanism-Based Concepts of Size and Maturity in PharmacokineticsAnnual Review of Pharmacology and Toxicology, 2008
- Nephropathic Cystinosis in Adults: Natural History and Effects of Oral Cysteamine TherapyAnnals of Internal Medicine, 2007
- Measurement of cystine in granulocytes using liquid chromatography-tandem mass spectrometryClinical Biochemistry, 2007
- Maximum likelihood estimation in nonlinear mixed effects modelsComputational Statistics & Data Analysis, 2005
- Steady‐state pharmacokinetics and pharmacodynamics of cysteamine bitartrate in paediatric nephropathic cystinosis patientsBritish Journal of Clinical Pharmacology, 2003
- CystinosisNew England Journal of Medicine, 2002
- R: A Language for Data Analysis and GraphicsJournal of Computational and Graphical Statistics, 1996
- Detection and Characterization of a Transport System Mediating Cysteamine Entry into Human Fibroblast LysosomesJournal of Biological Chemistry, 1995